作為商業(yè)發(fā)展副總裁，林劍將負(fù)責(zé)領(lǐng)導(dǎo)堯唐生物BD、公共關(guān)系及投資者關(guān)系部的整體管理，根據(jù)公司總體戰(zhàn)略發(fā)展需要，負(fù)責(zé)制定及執(zhí)行伙伴關(guān)系及企業(yè)投資策略、建立創(chuàng)新能力以及整體相關(guān)業(yè)務(wù)生態(tài)系統(tǒng)，通過合作為公司帶來優(yōu)質(zhì)的研發(fā)及商業(yè)資源和投資機(jī)會，推動公司業(yè)務(wù)增長。

林劍本科畢業(yè)于山東大學(xué)國家生物基地班生物技術(shù)專業(yè)，擁有中國科學(xué)院生物技術(shù)與醫(yī)藥專業(yè)碩士學(xué)位和中歐商學(xué)院MBA，法國蒙彼利埃大學(xué)就讀醫(yī)藥健康管理學(xué)博士。

在加入堯唐生物之前，林劍曾在康寧杰瑞擔(dān)任商務(wù)合作部門負(fù)責(zé)人，負(fù)責(zé)公司全球BD以及戰(zhàn)略聯(lián)盟管理業(yè)務(wù)；并曾服務(wù)于多家跨國制藥企業(yè)包括日本衛(wèi)材、勃林格殷格翰、強(qiáng)生和諾華等公司，在商務(wù)拓展、戰(zhàn)略制定、投資并購、聯(lián)盟管理、市場銷售及產(chǎn)品管理領(lǐng)域積累了豐富的經(jīng)驗(yàn)。

林劍在生物制藥行業(yè)經(jīng)驗(yàn)超過15年，他曾主導(dǎo)并參與20多項(xiàng)國內(nèi)及全球?qū)ν夂献?，涵蓋license許可交易、戰(zhàn)略合作以及股權(quán)交易等多種商業(yè)模式，總交易金額超過10億美金，維護(hù)并管理數(shù)十家全球合作伙伴關(guān)系包括輝瑞、賽諾菲、德國默克、中國石藥、先聲、以嶺及京東健康等知名企業(yè)。

As Vice President of Business Development, Colin Lin will be responsible for leading the overall BD, public relations, and investor relations departments in Yoltech, he will bring high-quality R&D and commercial resources and investment opportunities to the company through various of partnership including out-licensing and financing,  to empower pipeline competence and promote business growth.

Colin started career from Novartis internship and then got MT offer from Johnson & Johnson Medical. Led multiple healthcare licensing, strategy, and equity projects in Eisai. Acted as brand owner of company’s best selling product in Boehringer Ingelheim. As head of BD at Alphamab, led 10+ deals, including inlicensing, global out-licensing, and multi-spectrum deals (total deal size nearly $1.0 Bn). 

Colin has 15 years of  pharmaceutical industry experience in business development, strategy & alliance management, etc. Led to complete a number of licensing deals, strategic cooperation and equity investment projects, owned a wealth of experience across all parts of business development value chain, familiar with various of disease fields. He is PhD candidate in montpellieruniversity, received a master's degree in biomedicine from the China Academy of Science and a MBA degree in CEIBS.